EGFR and colorectal carcinoma: Activation of Wnt/β‐catenin signaling pathway enhances CRC cell stemness and renders them resistant to 5‐flurouracil (5‐FU) and oxaliplatin.[41] In addition, in CRC drug resistance, METTL3‐mediated m6A modification and hnRNPA2B1 reading are involved in cetuximab (an anti‐EGFR monoclonal antibody) resistance through activation of Wnt/β‐catenin signaling.